WILLIAMS-SONOMA, INC. ANNOUNCES STRATEGIC ACQUISITION TO EXPAND IN DORM MARKET
SAN FRANCISCO--(BUSINESS WIRE)--Williams-Sonoma, Inc. (NYSE: WSM) the world's largest digital-first, design-led and sustainable home retailer, announced today the acquisition of the intellectual property of Dormify, a trusted online retailer and content resource for college students and young adults seeking curated, space-saving home solutions. This strategic acquisition reinforces Williams-Sonoma, Inc.'s ongoing commitment to long-term growth and showcases the company's ability to pursue targeted opportunities that capture market share and unlock white space across key demographic and lifestyle segments.
'The acquisition of Dormify's intellectual property aligns with our strategy to build and acquire brands that meet customers at every stage of life across various aesthetics,' said Laura Alber, President and CEO of Williams-Sonoma, Inc. 'We look forward to integrating our operational excellence, in-house design capabilities, digital expertise, and world-class customer service into Dormify to accelerate the brand's growth and scale its reach.'
Williams-Sonoma, Inc. will relaunch Dormify in 2026.
ABOUT WILLIAMS-SONOMA, INC.
Williams-Sonoma, Inc. is the world's largest digital-first, design-led and sustainable home retailer. The company's products, representing distinct merchandise strategies — Williams Sonoma, Pottery Barn, Pottery Barn Kids, Pottery Barn Teen, West Elm, Williams Sonoma Home, Rejuvenation, Mark and Graham, and GreenRow — are marketed through e-commerce websites, direct-mail catalogs and retail stores. These brands are also part of The Key Rewards, our loyalty and credit card program that offers members exclusive benefits across the Williams-Sonoma family of brands. We operate in the U.S., Puerto Rico, Canada, Australia and the United Kingdom, offer international shipping to customers worldwide, and have unaffiliated franchisees that operate stores in the Middle East, the Philippines, Mexico, South Korea and India, as well as e-commerce websites in certain locations.
This press release contains forward-looking statements that involve risks and uncertainties, as well as assumptions that, if they do not fully materialize or are proven incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. Such forward-looking statements include statements relating to Williams-Sonoma, Inc.'s acquisition of Dormify's intellectual property, the anticipated benefits of the acquisition, the ability to integrate the company's operations into Dormify, the anticipated growth and scalability of the Dormify brand, and the timing of the relaunch of Dormify. These forward-looking statements are based on current expectations and involve risks and uncertainties.
The risks and uncertainties that could cause the company's results to differ materially from those expressed or implied by such forward-looking statements include the risks that: the company may be unable to achieve the anticipated benefits of the transaction; initiatives with Dormify may distract management from other operations; customer loss and business disruption (including, without limitation, difficulties in maintaining relationships with Dormify customers until the relaunch) may be greater than expected; and other risks and uncertainties described more fully in our public announcements, reports to stockholders and other documents filed with or furnished to the SEC, including our Annual Report on Form 10-K for the fiscal year ended February 2, 2025 and all subsequent quarterly reports on Form 10-Q and current reports on Form 8-K. All forward-looking statements in this press release are based on information available to us as of the date hereof, and the company assumes no obligation to update these forward-looking statements.
WSM-PR
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
These Energy Dividend Stocks Print Money
Fee-based arrangements support 90% of Energy Transfer's earnings. Kinder Morgan gets about 95% of its earnings from stable sources. Williams receives roughly 91% of its earnings from predictable contracts. 10 stocks we like better than Energy Transfer › Cash flows across the energy sector tend to be more variable due to commodity price volatility. However, some energy stocks just print money because their business models have minimal direct exposure to commodity prices. That gives them the cash to pay lucrative dividends. Energy Transfer (NYSE: ET), Kinder Morgan (NYSE: KMI), and Williams (NYSE: WMB) operate money-printing energy midstream assets. Because of that, they're ideal options for investors seeking to generate passive income. Energy Transfer operates a nationwide footprint of crucial midstream assets. Its more than 130,000-mile pipeline network moves oil, natural gas, and other commodities from production basins to market centers in the U.S. and beyond through its export terminals. Fee-based contracts and government-regulated rate structures support 90% of its earnings. Because of that, the master limited partnership (MLP) prints cash. The midstream giant generated more than $2.3 billion in distributable cash flow during the first quarter and distributed about $1.1 billion of that money to investors. Energy Transfer used its retained cash flow to invest in expansion projects ($945 million of growth capital spending) and maintain its strong balance sheet. The MLP is investing heavily to expand its already massive midstream footprint. It's spending $5 billion on growth projects this year, which are expected to come online through the end of next year. That should drive a meaningful uptick in its stable cash flows in 2026 and 2027. Energy Transfer's growing sources of stable cash flow should enable the MLP to continue increasing its distribution. It's aiming to raise its more than 7%-yielding payout by 3% to 5% per year. Kinder Morgan owns an irreplaceable energy infrastructure portfolio. It operates one of the largest natural gas pipeline networks in the country and is a leader in handling refined petroleum products and transporting carbon dioxide. Take-or-pay contracts, which entitled Kinder Morgan to payment regardless of volumes or prices, back 64% of the company's cash flow. Meanwhile, hedging contracts that guarantee prices lock in another 5% of its cash flow. Kinder Morgan also gets 26% of its earnings from fee-based sources, most of which have minimal exposure to volume fluctuations. As a result, the company's assets pump out a lot of stable cash flow each quarter. Kinder Morgan generated $1.2 billion in cash flow from operations during the first quarter, covering its dividend outlay of $642 million by roughly 2 times. That enabled it to retain meaningful excess free cash flow to fund expansion projects. The pipeline giant currently has $8.8 billion worth of expansion projects under construction, which are expected to enter commercial service through 2030. They will grow the company's sources of stable cash flow, which should enable it to continue increasing its more than 4%-yielding dividend. Williams operates one of the country's largest natural gas infrastructure platforms. It owns key interstate pipelines (including the Transco system that supplies gas to major markets along the East Coast). It also has gathering and processing (G&P) operations in key production basins, as well as other related infrastructure. Highly regulated transmission and deepwater assets account for 48% of Williams' cash flow, giving it a very stable foundation. Meanwhile, fee-based G&P assets supply it with another 43% of its cash flow. Williams also layers in hedges to backstop its more price-sensitive assets. The gas infrastructure company generated nearly $1.5 billion in available funds from operations during the first quarter. That covered its more than 3%-yielding dividend by a super comfy 2.4 times. Williams' lower dividend payout ratio enabled it to retain lots of cash to fund expansion projects and maintain its financial flexibility. Williams is working on a huge slate of growth projects. It has several projects underway to expand Transco and its other gas transmission pipelines, and it's connecting new deepwater projects in the Gulf to its infrastructure. Williams is also building a natural gas power plant to support the rising power demand of AI data centers. These projects will fuel cash-flow growth through 2030, giving Williams more power to increase its dividend. Energy midstream companies like Energy Transfer, Kinder Morgan, and Williams primarily operate fee-based assets that print cash. Because of that, these energy infrastructure companies can pay attractive and growing dividends. That makes them ideal options for investors seeking stable and steadily rising passive income streams. Before you buy stock in Energy Transfer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Energy Transfer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $664,089!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $881,731!* Now, it's worth noting Stock Advisor's total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Matt DiLallo has positions in Energy Transfer and Kinder Morgan. The Motley Fool has positions in and recommends Kinder Morgan. The Motley Fool has a disclosure policy. These Energy Dividend Stocks Print Money was originally published by The Motley Fool Sign in to access your portfolio
Business Upturn
an hour ago
- Business Upturn
OGN FRAUD ALERT: Organon & Co. Investors are Reminded of Ongoing Securities Fraud Class Action — Contact BFA Law by July 22 Legal Deadline (NYSE:OGN)
NEW YORK, June 22, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Organon & Co. (NYSE: OGN) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Organon you are encouraged to obtain additional information by visiting Investors have until July 22, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Organon securities. The case is pending in the U.S. District Court for the District of New Jersey and is captioned: Hauser v. Organon & Co., et al. , No. 25-cv-05322. Why was Organon Sued for Securities Fraud? Organon is a global healthcare company focused on women's health that has historically rewarded its shareholders with a healthy dividend. In October 2024, Organon completed a $1.2 billion acquisition of Dermavant, a biopharmaceutical company focused on dermatological conditions. As alleged, while the acquisition increased Organon's debt, the Company assured investors it would maintain its dividend, which Organon asserted was its '#1 capital allocation priority.' In truth, Organon had shifted its capital allocation priority after the Dermavant acquisition to focus on reducing its debt, ultimately leading the Company to severely cut its dividend. The Stock Declines as the Truth is Revealed On May 1, 2025, Organon announced that management reset the Company's dividend payout from $0.28 per share to $0.02 per share. Organon's CEO explained that the Company 'reset our capital allocation priorities to accelerate progress towards deleveraging' and that '[b]y deleveraging more rapidly, we will continue to strengthen the future prospects of the company.' Organon's CFO added, '[t]he biggest issues we face . . . relate to managing our leverage and relate to growth. And we need capital to solve both of those issues, and so returning capital to shareholders is right now, less of a priority.' On this news, the price of Organon stock declined roughly 27%, from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025. Click here if you suffered losses: What Can You Do? If you invested in Organon you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Or contact:Ross Shikowitz [email protected] 212-789-3619
Business Upturn
an hour ago
- Business Upturn
IOVA FRAUD ALERT: Iovance Biotherapeutics Investors are Reminded of Ongoing Securities Fraud Class Action — Contact BFA Law by July 14 Legal Deadline (NASDAQ:IOVA)
NEW YORK, June 22, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Iovance you are encouraged to obtain additional information by visiting Investors have until July 14, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Iovance securities. The case is pending in the U.S. District Court for the Northern District of California and is captioned Sundaram v. Iovance Biotherapeutics, Inc., et al. , No. 25-cv-04177. Why was Iovance Sued for Securities Fraud? Iovance is a commercial-stage biopharmaceutical company focused on the development of treatments for melanoma and other solid tumor cancers. The Company commercially launched its key melanoma treatment Amtagvi in February 2024. Iovance administers Amtagvi at the Company's authorized treatment centers ('ATCs'). As alleged, Iovance repeatedly touted its ATCs as a driver of demand for Amtagvi. In truth, Iovance's ATCs were experiencing long timelines to begin treating patients with Amtagvi, and ineffective patient identification and patient selection for treatment was causing high patient drop-offs at the ATCs. The Stock Declines as the Truth is Revealed On May 8, 2025, Iovance reported disappointing financial results for 1Q25 and announced it was 'revising full-year 2025 revenue guidance.' The Company blamed 'recent launch dynamics,' including slow 'treatment timelines for new ATCs' and 'the variable pace at which ATCs began treating patients,' which 'differs from center to center.' Iovance also blamed the poor results on high 'patient drop-off' due to inadequate 'patient selection' for treatment. On this news, the price of Iovance stock declined more than 44%, from $3.17 per share on May 8, 2025, to $1.75 per share on May 9, 2025. Click here if you suffered losses: What Can You Do? If you invested in Iovance you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Or contact:Ross Shikowitz [email protected] 212-789-3619
